INCRESYNC Trademark

Trademark Overview

On Monday, September 29, 2008, a trademark application was filed for INCRESYNC with the United States Patent and Trademark Office. The USPTO has given the INCRESYNC trademark a serial number of 77580826. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 18, 2013. This trademark is owned by Takeda Pharmaceutial Company Limited. The INCRESYNC trademark is filed in the Pharmaceutical Products category with the following description:

Orally administered pharmaceutical preparations for the treatment and prevention of diabetic diseases, namely, type II diabetes, excluding preparations for the treatment of growth factor deficiency
incresync

General Information

Serial Number77580826
Word MarkINCRESYNC
Filing DateMonday, September 29, 2008
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 18, 2013
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 17, 2009

Trademark Statements

Goods and ServicesOrally administered pharmaceutical preparations for the treatment and prevention of diabetic diseases, namely, type II diabetes, excluding preparations for the treatment of growth factor deficiency

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 2, 2008
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTakeda Pharmaceutial Company Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressChuo-ku, Osaka
JP
Party NameTakeda Pharmaceutial Company Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressChuo-ku, Osaka
JP

Trademark Events

Event DateEvent Description
Monday, March 18, 2013ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, March 18, 2013ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 23, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 22, 2012EXTENSION 2 GRANTED
Tuesday, August 7, 2012EXTENSION 2 FILED
Monday, August 20, 2012CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 7, 2012TEAS EXTENSION RECEIVED
Friday, January 27, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 25, 2012EXTENSION 1 GRANTED
Wednesday, January 25, 2012EXTENSION 1 FILED
Wednesday, January 25, 2012TEAS EXTENSION RECEIVED
Tuesday, August 16, 2011NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, July 1, 2011TTAB RELEASE CASE TO TRADEMARKS
Friday, July 1, 2011OPPOSITION TERMINATED NO. 999999
Friday, July 1, 2011OPPOSITION DISMISSED NO. 999999
Monday, June 6, 2011PAPER RECEIVED
Monday, September 14, 2009OPPOSITION INSTITUTED NO. 999999
Thursday, April 9, 2009EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, March 17, 2009PUBLISHED FOR OPPOSITION
Wednesday, February 25, 2009NOTICE OF PUBLICATION
Tuesday, February 10, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, February 9, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 6, 2009ASSIGNED TO EXAMINER
Friday, January 30, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 30, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 30, 2009ASSIGNED TO LIE
Friday, January 23, 2009TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 28, 2008NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, December 28, 2008NON-FINAL ACTION E-MAILED
Sunday, December 28, 2008NON-FINAL ACTION WRITTEN
Sunday, December 28, 2008ASSIGNED TO EXAMINER
Friday, October 3, 2008NOTICE OF PSEUDO MARK MAILED
Thursday, October 2, 2008NEW APPLICATION ENTERED IN TRAM

Related Keywords

incresync treatment preparations excluding diabetes growth deficiency type factor diseases pharmaceutical